Histogen
David H. Crean has a long and accomplished history in the business world. David is currently the Chairman at Theirtogen, a position they have held since 2015. Prior to that, they were with Biocom California from 2014-2015, Renaissance Executive Forums from 2012-2014, Phoenix Molecular Designs from 2009-2012, MediciNova, Inc. from 2007-2009, Lenire Biosciences from 2005-2007, Cardiff Advisory LLC from 2003-2005, Forbes Los Angeles Business Council from 2001-2003, and California Life Sciences (CLS) from 1999-2001.
David H. Crean has a Master of Business Administration (MBA) from Pepperdine Graziadio Business School, a Doctor of Philosophy (Ph.D.) in Biophysics from State University of New York at Buffalo - School of Pharmacy and Pharmaceutical Sciences, and a Master of Science (M.S.) in Natural Sciences / Oncology from University at Buffalo. David also has a Bachelor of Science (B.S.) in PreMed & Sports Medicine from Canisius College and is certified by the FINRA (Financial Industry Regulatory Authority) in Series 79 - Investment Banking Representative and Series 63 - Uniform State Law Securities License.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Histogen
Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.